Press release Communiqué de presse
Press release Communiqué de presse
September 9, 2020 9 September, 2020
Sernova Announces Up to $3 Million Private Placement Financing with a Lead Order of $2 Million
THIS NEWS RELEASE IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR
DISSEMINATION IN THE UNITED STATES.
Source: Sernova Corp
September 9, 2020 9:00 a.m. EST
LONDON, ONTARIO – September 9, 2020 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical-stage regenerative medicine therapeutics company, is pleased to announce that the Company has secured a $2 million lead order in connection with a proposed non-brokered private placement.
“Strategic investors approached Sernova management following successful achievement of key milestones to provide additional financing to accelerate our recently acquired cellular local immune protection technology to the clinic with the goal to eliminate the need for systemic immune protection medications for cell therapy therapeutic applications as well as further support our U.S. Phase I/II diabetes clinical trial at the University of Chicago,” said Dr. Philip Toleikis, President & CEO Sernova Corp. “The favourable terms of the lead order also reflect investors’ optimism for Sernova’s clinical trial progression.”
Up to 10 million units of the Company would be issued in the private placement at a price of $0.30 per unit for up to $3.0 million. Each unit would consist of one common share and one full warrant. Each warrant would be exercisable into a common share at a price of $0.35 per share for a period of 24 months from the date of issue, subject to abridgment of the exercise period if the 10-day volume-weighted average price of the Company’s shares exceeds $0.50 per share.
Investors qualified under applicable securities laws interested in participating in the private placement may contact the Company (see the contact information provided below). The terms and conditions of any subscription, including qualification criteria under applicable securities laws, will be set out in the subscription agreement for the private placement.
Offering proceeds will be used to accelerate development of our recently acquired cellular local immune protection technology, further our immune-protected diabetes stem cell-derived program and support the Company’s U.S. Phase I/II diabetes clinical trial.
All securities issued in connection with the private placement will be subject to a statutory hold period of four months. Completion of the private placement is subject to the receipt of customary approvals, including approval of the TSX Venture Exchange.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
ABOUT SERNOVA CORP.
Sernova Corp is developing regenerative medicine therapeutic solutions using a medical device (Cell Pouch™) and immune protected therapeutic cells/tissues (i.e. human donor cells, corrected human cells, and stem cell- derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through cellular production of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com.
ABOUT SERNOVA’S CELL POUCH SYSTEM
The Cell Pouch, as part of the Cell Pouch System, is a novel, proprietary, scalable, implantable macro- encapsulation device solution designed for the long-term survival and function of therapeutic cells. The device, upon implantation, is designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells, which then release proteins, hormones, or other factors as required to treat disease. Sernova is currently conducting a Phase I/II study at the University of Chicago and has demonstrated encouraging early safety and efficacy indicators. The Cell Pouch, in combination with therapeutic cells/tissues, has been shown to provide long-term safety and efficacy in preclinical models of diabetes, hemophilia A and other indications supporting our therapeutics platform.
For further information contact:
Dominic Gray Sernova Corp Tel: (519) 858-5126 email@example.com www.sernova.com
This release contains statements that, to the extent they are not recitations of historical facts, may constitute “forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the Company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management’s beliefs with respect to future events and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova’s actual results, performances or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors could include, but are not limited to, the Company’s ability to secure additional financing and licensing arrangements on reasonable terms, or at all; ability to conduct all required preclinical and clinical studies for the Company’s Cell Pouch System and/or related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to execute its business strategy and successfully compete in the market; and the inherent risks associated with the development of biotechnology combination products generally. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the Company’s quarterly and annual filings available on www.sedar.com for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.